Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-Methoxy-N,N-dimethyltryptamine Metabolism and Pharmacokinetics

Схожие документы

• Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status
  по: Jiang, Xi-Ling, et al.
  Опубликовано: (2013)
• Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice
  по: Shen, Hong-Wu, et al.
  Опубликовано: (2011)
• Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms
  по: Jiang, Xi-Ling, et al.
  Опубликовано: (2016)
• Behavioral and Pharmacokinetic Interactions Between Monoamine Oxidase Inhibitors and the Hallucinogen 5-Methoxy-N,N-dimethyltryptamine
  по: Halberstadt, Adam L.
  Опубликовано: (2016)
• Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions
  по: Shen, Hong-Wu, et al.
  Опубликовано: (2010)